文章摘要
王淑敏,马健,金亚明.射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究[J].南京中医药大学学报(自然科学版),2017,33(5):535-537.
射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究
Clinical Observation on Modified Sheganmahuang Tang Plus Symbicort in Treating the Acute Attack of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
投稿时间:2017-05-11  修订日期:2017-06-20
DOI:
中文关键词: 哮喘-慢性阻塞性肺疾病重叠综合征  射干麻黄汤  信必可
英文关键词: asthma-chronic obstructive pulmonary disease overlap syndrome  Sheganmahuang Tang  symbicort
基金项目:
作者单位
王淑敏1,马健1,金亚明2 1.南京中医药大学基础医学院江苏 南京 2100232.泰州市中医院呼吸科江苏 泰州 225300 
摘要点击次数: 48
全文下载次数: 67
中文摘要:
      目的 观察射干麻黄汤联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)急性发作期的临床疗效。方法 将42例痰湿阻肺证ACOS患者按随机数字法分为试验组(22例)和对照组(20例),在吸氧、止咳化痰、扩张支气管、抗感染等常规西药对症治疗基础上,对照组予信必可吸入,试验组予射干麻黄汤联合信必可治疗,疗程为4周,观察2组治疗效果。结果 临床疗效上,试验组和对照组患者的总有效率为96.00%和65.00%,组间比较,P<0.05;第1秒用力呼气量占预计值百分比(FEV1%)、第1秒用力呼气量占用力肺活量百分比(FEV1/FVC)较对照组明显升高,P<0.05,CO弥散量(DLCO)试验组较对照组略升高,P>0.05;哮喘控制测试评分(CAT)为(16±2)较对照组(20±2)显著降低,慢性阻塞性肺疾病评分(ACT)为(24±3)较对照组(16±2)显著提升,P<0.05~0.01;2组皆无严重不良反应。结论 射干麻黄汤联合信必可治疗ACOS急性发作期疗效满意,无严重不良反应,值得推广。
英文摘要:
      OBJECTIVE To observe the clinical effect of modified Sheganmahuang Tang plus symbicort in treating the acute attack of asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). METHODS Forty-two ACOS patients were divided into the experimental group (22 cases) and the control group (20 cases) according to the random number. On the basis of conventional western drug symptomatic treatment including oxygen inhalation, stopping cough and resolving phlegm, bronchus dilation, anti-infection, the control group was given symbicort inhalation, and the experimental group was given Sheganmahuang Tang plus symbicort. The treatment course was 4 weeks. the curative effects of both groups were observed. RESULTS In terms of clinical effect, the totally effective rates of the experimental group and the control group were 96.00% and 65.00%, respectively, and the difference between two groups was significant, P<0.05. The FEV1% and FEV1/FVC increased significantly compared with the control group, P<0.05. DLCO in the experimental group increased slightly higher than that in the control group, P>0.05; CAT score (16±2) decreased significantly compared with the control group (20±2); and the ACT score (24±3) increased significantly compared with the control group (16±2), P<0.05. The reoccurrence rate in the experimental group decreased significantly compared with the control group, P<0.05~0.01. Both groups reported no severe adverse event. CONCLUSION Sheganmahuang Tang plus symbicort achieves satisfactory curative effect in the treatment of acute attack of ACOS with no severe adverse event, which is worthy of spreading.
查看全文   查看/发表评论  下载PDF阅读器
关闭
微信公众号